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Objective
To evaluate the clinical and functional activity of patients
with rheumatoid arthritis at one and two years after start-
ing anti-TNF therapy.
Patients and methods
This is a retrospective study of 50 RA patients, who
started ANTI-TNF theraphy between June 2006 and july
2009. The main variables in the study were: DAS28,
HAQ and pain VAS. We analyzed evolution after 1 year
and 2 years from the beginning of the treatment. The
comparison with the basal state was made with Student’s
t test. The statistical study was analyzed by the SPSS 18,0.
Results
The study includes 50 patients, 66% female, with RF in
76% and erosions in 64%, treated with etanercept (28),
adalimumab (13) and infliximab (9). Most of them (70%)
had recieved at least 2 FAMES before biological. In the
below table we compare changes in clinical parameters for
different biologics after one and two years.
Conclusions
All anti-TNF significantly improve disease activity, func-
tional status and pain VAS after the first year. This
improvement continues but not significantly increases the
second year.
Rheumatology Unit, Valme University Hospital, Sevilla, Spain
Table 1
BASAL 12 MONTHS (p basal-12M) 24 MONTHS (p 12M-24M)
EVA (mm)
-Etanercept 72,21±16,78 33,20 ± 20,05 (p<0,005) 31,95 ± 27,12 (p=0,39)
-Adalimumab 69,83±20,54 45,00 ± 28,33 (p=0,21) 51,00 ± 28,44 (p=0,16)
-Infliximab 69,78±15,45 42,56 ± 23,41 (p=0,015) 37,71 ± 23,95 (p=0,86)
DAS28
-Etanercept 5,88 ± 1,05 2,85 ± 1,16 (p<0,005) 3,09 ± 1,52 (p=0,98)
-Adalimumab 5,73 ± 1,51 4,05 ± 2,43 (p=0,011) 3,90 ± 1,88 (p=0,22)
-Infliximab 6,03 ± 1,87 4,08 ± 1,61 (p=0,021) 3,83 ± 1,66 (p=0,91)
HAQ
-Etanercept 1,61 ± 0,61 0,77 ± 0,64 (p <0,005) 0,80 ± 0,73 (p = 0,87)
-Adalimumab 1,63 ± 0,58 1,35 ± 0,63 (p = 0,05) 1,38 ± 0,70 (p =0,58)
-Infliximab 1,45 ± 0,74 1,24 ± 0,72 (p = 0,20) 1,28 ± 0,69 (p = 0,34)
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